Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy

Clinical Infectious Diseases

Volumn 61, Issue 7, 2015, Pages 1169-1178

  Martínez Bonet, Marta ^a,b,c,d   Puertas, Maria Carmen ^e   Fortuny, Claudia ^f   Ouchi, Dan ^e   Mellado, Maria José ^g   Rojo, Pablo ^h   Noguera Julian, Antoni ^f   Muñoz Fernández, Ma Angeles ^a,b,c,d   Martinez Picado, Javier ^e,i,j  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d Spanish HIV HGM BioBank ^*  (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^j INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

early antiretroviral therapy; HIV 1; vertical infection; viral reservoir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; VIRUS DNA; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CHILD; EARLY CHILDHOOD INTERVENTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVIRAL RESERVOIR; RETROSPECTIVE STUDY; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LOAD; AGE; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INFANT; NEWBORN; STATISTICS AND NUMERICAL DATA; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

AGE FACTORS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84942134668     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ456     Document Type: Article

References (40)

1. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet 2007; 370:68-80
2. Mofenson LM, Korelitz J, MeyerWA III, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997; 175:1029-38
3. McIntosh K, Shevitz A, Zaknun D, et al. Age-and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J 1996; 15:1087-91
4. Rich KC, Fowler MG, Mofenson LM, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics 2000; 105:e8
5. Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997; 130:388-93
6. Erkeller-Yuksel FM, Deneys V, Yuksel B, et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992; 120(2 Pt 1): 216-22
7. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Available at: http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf. Accessed 28 June 2015
8. Faye A, Le Chenadec J, Dollfus C, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39:1692-8
9. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004; 350: 2471-80
10. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-44
11. Prendergast A, Mphatswe W, Tudor-Williams G, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008; 22:1333-43
12. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/. Accessed 28 June 2015
13. Panel on Antiretroviral Therapy and Medical Management of HIVinfected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed 28 June 2015
14. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23:381-90
15. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004; 78:968-79
16. Aldhous MC, Raab GM, Doherty KV, Mok JY, Bird AG, Froebel KS. Age-related ranges of memory, activation, and cytotoxic markers on CD4 and CD8 cells in children. J Clin Immunol 1994; 14:289-98
17. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112: 973-80
18. Bunders MJ, van der Loos CM, Klarenbeek PL, et al. Memory CD4+ CCR5+ T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood 2012; 120:4383-90
19. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211
20. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369: 1828-35
21. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948
22. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012; 109:9523-8
23. Klein N, Sefe D, Mosconi I, et al. The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS One 2013; 8:e76582
24. Ananworanich J, Robb ML. The transient HIV remission in the Mississippi baby: why is this good news? J Int AIDS Soc 2014; 17:19859
25. Garcia-Merino I, de Las Cuevas N, Jimenez JL, et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009; 6:27
26. de Jose MI, Jimenez de Ory S, Espiau M, et al. A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe). BMC Infect Dis 2013; 13:2
27. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00032890.htm. Accessed 28 June 2015
28. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAARTsuppressed subjects. Nat Med 2010; 16:460-5
29. Puertas MC, Salgado M, Moron-Lopez S, et al. Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. AIDS 2014; 28:2157-9
30. Pollet DE, Saman EL, Peeters DC, et al. Confirmation and differentiation of antibodies to human immunodeficiency virus 1 and 2 with a strip-based assay including recombinant antigens and synthetic peptides. Clin Chem 1991; 37(10 Pt 1):1700-7
31. Team Rc. R: A language and environment for statistical computing. Available at: http://www.R-project.org/. Accessed 28 June 2015
32. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28:1015-20
33. Jain V, HartogensisW, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208: 1202-11
34. Persaud D, Palumbo PE, Ziemniak C, et al. Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012; 26:1483-90
35. Persaud D, Patel K, Karalius B, et al. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 2014; 168: 1138-46
36. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis 2014; 210:1529-38
37. Brophy J, Chun TW, Samson L, et al. Impact of early initiation of combination antiretroviral therapy on measures of virus in peripheral blood of vertically HIV-1-infected children. In: 20th International AIDS Conference. Melbourne, Australia, 2014
38. Zanchetta M, Anselmi A, Vendrame D, et al. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther 2008; 13:47-55
39. Giacomet V, Trabattoni D, Zanchetta N, et al. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet 2014; 384:1320
40. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202: 1553-61